Axsome Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Axsome Therapeutics Inc 's ROA in the second quarter of 2026?
Axsome Therapeutics Inc recorded a cumulative net loss of $-192 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -27.05%.

However, within the Healthcare sector 402 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3602, from total ROA ranking in the first quarter of 2026 at 4243.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	19.02 %	19.6 %	22.18 %	23.86 %	17.85 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-192	-188	-183	-230	-247
Return On Assets (TTM)	-27.05 %	-27.77 %	-28.23 %	-37.17 %	-42.18 %
AXSM's Total Ranking	# 3602	# 4243	# 3867	# 3973	# 4138
Total Assets (TTM) in million	761	714	690	669	640
Seq. Total Assets Change	6.7 %	3.45 %	3.07 %	4.61 %	7.23 %
Seq. Net Income Change	-	-	-	-	-

AXSM's 5 Years Annual ROA >> Back to AXSM Management Effectiveness >> Compare AXSM ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 151
Sector	# 403
Overall	# 3553

Return On Assets Statistics
High	Average	Low
-27.05 %	-72.65 %	-152.6 %
(Jun 30 2026)		(Dec 31 2018)

Financial Statements
Axsome Therapeutics Inc 's Assets	$ 761 million	AXSM's Balance sheet
Axsome Therapeutics Inc 's Income	$ -51 million	Quarterly AXSM's Income Statement
AXSM's Income by Division		See AXSM's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	22.18 %	-3.23 %	76.01 %	277.6 %	-78.09 %
Total Assets in million	690	565	583	331	88
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-183	-287	-239	-187	-130
Annual Return On Assets	-26.55 %	-50.87 %	-41 %	-56.45 %	-148.55 %

AXSM's 5 Years Annual ROA >> Back to AXSM Management Effectiveness >> Compare AXSM ROA to its Competitors

More Return On Assets Ratios
AXSM's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AXSM's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AXSM's Competitors
Subscribers only: Roa for Axsome Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for AXSM's Customers

You may also want to know
AXSM's Roi	AXSM's Inventory Turnover Ratio	AXSM's Growth Rates	AXSM's Dividend Comparisons
	AXSM's Profitability Ratios	AXSM's Asset Turnover Ratio	AXSM's Dividend Growth
AXSM's Roe	AXSM's Valuation Ratios	AXSM's Financial Strength Ratios	AXSM's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:22:20+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.